GSK enters agreement to acquire IDRx, Inc.
Jan 13, 2025 · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for …
GSK Enters Agreement to Acquire IDRx, Inc. - Yahoo Finance
Jan 13, 2025 · IDRX-42 has demonstrated activity against all key primary and secondary KIT mutations, designed to improve outcomes for patients with GIST. This breadth of mutational …
GSK enters agreement to acquire IDRx, Inc. – IDRx
Jan 13, 2025 · IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies; Acquisition adds to …
JP Morgan 2025: GSK acquires IDRx in $1.15bn deal - Yahoo Finance
Jan 13, 2025 · GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to …
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
Jan 13, 2025 · To purchase 100% of IDRx’s outstanding equity interests, GSK will make a $1 billion upfront payment plus the promise of up to $150 million in a success-based regulatory …
GSK to Buy US Biotech Firm IDRx for up to $1.15 Billion - U.S. News
Jan 13, 2025 · (Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a …
GSK nears $1bn deal for biotech developing drug for rare tumour
Jan 8, 2025 · The UK group is in advanced talks to buy privately owned biotech IDRx, which has venture capital firms Andreessen Horowitz and RA Capital as well as private equity giant …
GSK Enters Agreement to Acquire IDRx, Inc. | Business Wire
Jan 13, 2025 · Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition …
GSK to buy US biotech firm IDRx for up to $1.15 billion | Reuters
Jan 13, 2025 · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …
GSK to Buy US Cancer Biotech IDRx for Up to $1.15 Billion (1)
Jan 13, 2025 · GSK Plc agreed to buy US biotech IDRx for as much as $1.15 billion to gain new cancer medicines. The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for …
- Some results have been removed